Clinical assessments based on GINA-derived symptom scores provide limited resolution of the molecular mechanisms that govern asthma progression and response to therapy. Circulating microRNAs (miRNAs) have known roles in immune regulation and airway remodeling, but their relationship to longitudinal, treatment-specific asthma control in children has not been well characterized. This study examined whether baseline serum miRNA profiles can predict longitudinal asthma control and discriminate well-controlled from uncontrolled disease within treatment arms of a pediatric randomized trial.
The analysis used baseline serum miRNA sequencing data from 491 children enrolled in the Childhood Asthma Management Program (CAMP), a randomized clinical trial comparing budesonide versus placebo. Asthma control was assessed using a composite GINA-based symptom score at baseline and at 2, 4, 8, and 12 months of follow-up.
A panel of 266 detectable miRNAs was analyzed. To identify miRNAs associated with longitudinal ordinal asthma control, the investigators fitted cumulative link mixed models across the miRNAs, adjusting for follow-up time, baseline control status, and randomized treatment assignment. Models were therefore designed to detect associations between baseline circulating miRNA abundance and subsequent ordinal symptom severity over multiple time points.
For classification of 12-month control status, Random Forest machine learning classifiers were trained separately within each treatment group using Group K-Fold cross-validation. This approach assessed the ability of baseline miRNA profiles to discriminate between well-controlled and uncontrolled asthma at 12 months while avoiding information leakage across grouped samples.
Validated miRNA target genes were subjected to pathway enrichment analysis using DAVID to infer potential biological pathways linked to the treatment-specific miRNA signatures.
Treatment-specific associations between baseline circulating miRNAs and longitudinal asthma control were observed.
In the budesonide arm, two notable associations were reported in the abstract: hsa-miR-1224-5p associated with lower symptom severity, and hsa-miR-199a-3p|hsa-miR-199b-3p associated with higher symptom severity. Importantly, these associations persisted through the 12-month follow-up time point, indicating a durable relationship between these baseline miRNAs and subsequent control status in children treated with budesonide.
The placebo arm demonstrated a broader set of associations; the abstract specifies that ten miRNAs were associated with symptom trajectories in that group, but it does not list those miRNAs in this summary.
Random Forest classifiers trained within treatment groups achieved mean area under the receiver operating characteristic curve (AUC) values of 0.776 for the budesonide group and 0.714 for the placebo group for prediction of 12-month control status. These results indicate moderate discrimination by baseline miRNA profiles, with somewhat better performance in the budesonide-treated participants.
Pathway enrichment analysis of validated targets revealed different patterns between treatment-associated miRNAs. Targets of miRNAs associated with the budesonide arm were enriched for glucocorticoid-responsive processes as well as MAPK/Ras signaling pathways, suggesting that these miRNAs may relate to mechanisms relevant to corticosteroid pharmacodynamics and signaling cascades implicated in airway biology.
By contrast, targets linked to placebo-associated miRNAs showed broader enrichment for general regulatory processes. The abstract does not provide the detailed list of enriched terms or the complete set of target genes; those details would be found in the full manuscript or supplementary materials.
Baseline circulating miRNAs distinguished trajectories of asthma control over 12 months and showed treatment-specific associations in this pediatric trial. The findings support the concept that circulating miRNA profiles can serve as complementary molecular markers for monitoring asthma control and may point to distinct biological pathways underlying treatment response versus natural history. The budesonide-associated signature specifically implicated glucocorticoid-responsive and MAPK/Ras signaling pathways, consistent with plausible mechanisms linking miRNA regulation to corticosteroid effects.
This work is reported as a preprint and has not undergone peer review; the authors note that the findings should not be used to guide clinical practice at this stage. The abstract states that the underlying data are not publicly available due to institutional restrictions on data sharing; access is limited to authorized members of the research team. The abstract does not provide the full list of placebo-associated miRNAs or the full pathway term lists, which limits interpretation from the abstract alone.
The study received support from multiple NIH awards listed in the article metadata. Ethical approval for the research was provided by the Ethics committee/IRB of Brigham and Women's Hospital (protocol #2017P001799), and the authors declare no competing interests. As a preprint on medRxiv, the article is posted under a CC-BY 4.0 International license and awaits formal peer review.
(For further methodological detail, the full preprint and supplementary materials should be consulted; the abstract summarizes primary findings but does not report all miRNA names, full model coefficients, or complete enrichment outputs.)